Innovation Spirits
We have independently developed 10 minimally invasive interventional treatment solutions targeting tricuspid valve diseases, mitral valve diseases, aortic valve diseases, and heart failure. All products are based on our original innovation and possess global patents and independent intellectual property rights.

Ken-Valve, our proprietary first-generation TAVR system, is designed for the treatment of severe aortic regurgitation (or combined with aortic stenosis). It is expected to address the needs of a larger patient pool than those TAVR systems that are indicated for the treatment of aortic stenosis alone.